NCT05318469 - Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 13, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma

Interventions

DRUG

Ivermectin

Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).

DRUG

Balstilmab

Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.

DRUG

Pembrolizumab

Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle

Trial Locations (1)

RECRUITING

Cedars-Sinai Medical Center, Los Angeles